TM editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

September is typically an ugly month for stocks. According to CNBC, on a 100-year basis, September is the only month that has a losing record. So take a break from market dynamics with these exciting biotech options. Biotech stocks march to a different tune. They can spike massively on positive news — be it key trial results or regulatory approvals. Of course, the opposite is also true and stocks can crash just as quickly on unexpected disappointments (delays, failed trials, regulatory rejection).

Now let’s see how the following hot stocks tick these two boxes:

Sorrento Therapeutics, Inc (Nasdaq:SRNE)

Sorrento is a clinical-stage biopharma developing new therapies to turn malignant cancers into manageable and possibly curable diseases. This includes everything from antibodies to pain management- including non-opioid pain medication ZTlido.

This medicated lidocaine plaster received FDA approval earlier this year and is now gearing up for launch. Top HC Wainwright analyst Ram Selvaraju (Profile & Recommendations) believes ZTlido “possesses best-in-class properties within the topical lidocaine niche.” He has a $40 price target on the stock- indicating massive upside potential of 647%!

The best part is that ZTlido uses far less lidocaine than in Lidoderm while efficacy is maintained due to improved adhesion and delivery. Overall, this ‘Strong Buy’ stock has a $21.67 average analyst price target (305%).

View SRNE Price Target & Analyst Rating Details

Tocagen Inc (Nasdaq:TOCA)

This cutting-edge biotech stock is at the forefront of cancer therapy. Tocagen is developing an RRV platform that can selectively deliver therapeutic genes into the DNA of cancer cells.

Now top Chardan Capital analyst Gbola Amusa (Profile & Recommendations) is out with a new bullish note. “We initiate coverage on Tocagen with a Buy rating (PT$30), on the risk-reward proposition on its pivotal, phase III, BTD/PRIME-designated therapy, Toca 511 & Toca FC, for high-grade gliomas (HGGs)” he wrote on August 30.

Print Friendly, PDF & Email